News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VG Life Sciences, Inc. (VRAL) Provides Additional Insight Into Clinical Trial


12/6/2012 11:13:20 AM

SAN MARINO, Calif.--(BUSINESS WIRE)--VG Life Sciences (OTC Pink: VRALD) (formerly known as Viral Genetics) has released its November 2012 Letter to Shareholders, published in its entirety below. In the letter as released to account for certain new developments, the Company’s President, Haig Keledjian, offers insight into the Company’s name change, recent restructuring, and an important milestone update into the Company’s Phase 1 physician-initiated clinical trial for ovarian cancer, and also other operational details.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES